Overview

Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance

Status:
Not yet recruiting
Trial end date:
2024-10-15
Target enrollment:
Participant gender:
Summary
Phase IV, open-label, single arm, unicenter and pilot study on virologically suppressed HIV infected adults with ETR resistance, to assess the efficacy of a Switch strategy from Etravirine (ETR) to Doravirine (DOR).
Phase:
Phase 4
Details
Lead Sponsor:
Fundacion Clinic per a la Recerca Biomédica